YEAR-END REPORT 2011 CHRONTECH PHARMA AB (PUBL)

 | Quelle: Fastilium Property Group AB Fastilium Property Group AB 

YEAR-END REPORT 2011 CHRONTECH PHARMA AB (PUBL)


  · Research and development costs amounted to SEK 15.2 (9.6) m
  · The loss after tax was SEK -20.2 (-14.6) m
  · Earnings per share were SEK -0.17 (-0.20)
  · The company had no net sales for the period
  · The controlled phase II clinical study of ChronVac-C® in combination with
standard-of-care has started.
  · ChronTech has entered as a partner in a collaborative project to improve on
HCV vaccines with Karolinska Institutet, University of Gothenburg, and Vecura,
which is funded by Vinnova by up to SEK 4.5 m. The project started in November
2010 and lasts for three years.
  · ChronTech Pharma has raised 25 million SEK (4 million USD) in a private
placement, 3.1 million SEK in a set-off issue, and 1.4 million SEK in two rights
issues.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.

Anhänge